nflammatory diseases aligns seamlessly with Xencor's pipeline development," said Bassil Dahiyat, Ph.D., chief executive officer of Xencor. "We expect that XmAb5871 will soon become the fifth XmAb-engineered antibody in clinical development. This program is a testament to the progress we've made expanding the XmAb platform into autoimmune disease with our CD32b technology, which is at the core of the XmAb5871 compound. The option deal structure allows us to continue to lead the development of XmAb5871 while also leveraging Amgen's experience in developing novel biologics for unmet medical needs."
About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit http://www.amgen.com/.
About XencorXencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb® antibody drug candidates into the clinic, including XmAb®5871 targeting CD32b and CD19 for autoimmune diseases, an anti-CD30 candidate XmAb®2513 which completed a Phase 1 clinical trial for the treatment of Hodgkin's Page: 1 2 3 Related biology technology :1
. Call for Applications: The Amgen Award for Science Teaching Excellence2
. Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits3
. Amgen to Provide Testimony at FDA Hearing on Biosimilars4
. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting5
. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines6
. Array BioPharma and Amgen Partner in Type 2 Diabetes7
. Amgen to Present at Lazard Capital Healthcare Conference8
. Amgen Announces Webcast of 2009 Third Quarter Financial Results9
. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference10
. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference11
. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)